Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035581
Status:
TERMINATED
Last Update Posted:
2013-04-17
First Post:
2002-05-03
Brief Title:
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Sponsor:
AIM ImmunoTech Inc
Organization:
AIM ImmunoTech Inc
Study Overview
Official Title:
A Multi-Center Randomized Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease
Status:
TERMINATED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label prospective randomized controlled study of the safety and efficacy including clinical immunologic and virologic assessments of adding Ampligen to HAART in HIV infected patients with CD4 counts 300 and HIV-1 plasma RNA 500 and 30000 copiesml PCR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None